Stent Placement Strategy and Post-Procedure Antiplatelet Regimen
For patients undergoing coronary stent placement, the default strategy is dual antiplatelet therapy (DAPT) with aspirin 75-100 mg plus clopidogrel 75 mg daily for up to 6 months in chronic coronary syndrome (CCS), followed by lifelong single antiplatelet therapy. 1
Standard Post-PCI Antiplatelet Regimen (No Oral Anticoagulation)
Initial DAPT Duration
- Default strategy: Aspirin 75-100 mg + clopidogrel 75 mg daily for up to 6 months after stenting in CCS patients 1
- Clopidogrel requires appropriate loading (600 mg loading dose or >5 days of maintenance therapy) 1
- This applies irrespective of stent type (drug-eluting or bare metal) 1
Modified Duration Based on Bleeding Risk
High bleeding risk patients (not at high ischemic risk):
- Discontinue DAPT at 1-3 months, then continue single antiplatelet therapy 1
- Very high bleeding risk: May consider stopping DAPT at 1 month 1
- Higher bleeding risk: Consider stopping at 3 months 1
Standard risk patients (neither high bleeding nor high ischemic risk):
- May consider stopping DAPT after 1-3 months 1
High ischemic risk patients (complex stenting scenarios):
- For complex left main, 2-stent bifurcation, suboptimal stenting, prior stent thrombosis, or known CYP2C19 polymorphisms: Consider prasugrel or ticagrelor instead of clopidogrel for the first 1-3 months, up to 6 months 1
Long-Term Maintenance (After DAPT Period)
Lifelong single antiplatelet therapy is mandatory:
- Aspirin 75-100 mg daily is the standard recommendation 1
- Clopidogrel 75 mg daily is an equally effective and safe alternative to aspirin 1
Special Consideration: Patients Requiring Oral Anticoagulation
Post-PCI Triple Therapy Strategy
For patients with atrial fibrillation or other OAC indications:
Recommended approach:
- Early aspirin cessation (≤1 week) after uncomplicated PCI 1
- Continue dual therapy with OAC + clopidogrel:
- Up to 6 months in patients not at high ischemic risk
- Up to 12 months in patients at high ischemic risk 1
- Then OAC alone lifelong 1
Alternative for very high thrombotic risk:
- Triple therapy (aspirin + clopidogrel + OAC) for ≥1 month may be considered when stent thrombosis risk outweighs bleeding risk, with total duration ≤6 months 1
Anticoagulant choice:
- Direct oral anticoagulants (DOACs) are preferred over warfarin when eligible 1
Key Clinical Pitfalls to Avoid
Do not routinely continue DAPT for 12 months in CCS patients - this is outdated; 6 months is now the default maximum 1
Do not use prasugrel in medically managed patients - it is only for PCI patients 2
Do not forget aspirin dose matters - use 75-100 mg daily, not higher doses, to minimize bleeding 2
Do not skip proton pump inhibitor (PPI) - recommended with DAPT to reduce GI bleeding 2
Do not use triple therapy longer than necessary in OAC patients - early aspirin cessation (≤1 week) is now preferred to reduce bleeding by ~30% 1
Algorithmic Approach
Step 1: Assess OAC indication
- If YES → Use early aspirin cessation strategy (≤1 week), then OAC + clopidogrel
- If NO → Proceed to Step 2
Step 2: Assess bleeding risk
- Very high bleeding risk → 1 month DAPT
- High bleeding risk → 1-3 months DAPT
- Standard risk → Up to 6 months DAPT
Step 3: Assess ischemic/procedural complexity
- Complex PCI (left main, bifurcation, suboptimal result) → Consider prasugrel/ticagrelor for first 1-3 months
- Standard PCI → Clopidogrel is appropriate
Step 4: Long-term maintenance
- Lifelong aspirin 75-100 mg OR clopidogrel 75 mg daily
- Add PPI for GI protection
The contemporary evidence strongly supports this risk-stratified, shorter-duration DAPT approach, which reduces major bleeding by 25-65% without increasing stent thrombosis or MI in most populations 3, 4. The shift away from routine 12-month DAPT reflects improved stent technology, better lesion preparation techniques, and recognition that bleeding carries significant prognostic impact 4, 5.